Antipsychotic drug use in 503 Chinese inpatients with schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 11, Issue 1, 2007, Pages 29-35

  Mao, Pei Xian ^a   Tang, Yi Lang ^a,b   Wang, Zhi Min ^a   Jiang, Feng ^a   Gillespie, Charles F ^b   Cai, Zhuo Ji ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; China; Clozapine; Diabetes; Risperidone; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE;

ADULT; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 33847785719     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600874360     Document Type: Article

References (53)

1. Tang YL. [Pharmacotherapy of schizophrenia]. In: Cai ZJ, Weng YZ, Tang YL, editors. Schizophrenia: From biology to treatments (in Chinese). Beijing, China: The Science Press; 2000. p 214-27 (in chinese).
2. Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004;58(1):61-7.
3. Potter WZ, Ko GN, Zhang LD, Yan WW. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berlin) 1989;99(Suppl):S87-91.
4. Wu TC, Tang GR. [Clinical use of antipsychotics and follow-up study]. Chin J Neuropsychiatr 1995;28:217 (in chinese).
5. Xu WR, Zhao BL, Cui Q, Gao MF. [A comparative study of clozapine and chlorpromazine on schizophrenia - a double-blind study]. Chin J Nerv Ment Dis 1985;11:222-4 (in chinese).
6. Lin RM, Song CS, Ji ZF, Jin SL, Luo Y. [Antipsychotic use in three psychiatric hospitals]. J Clin Psychol Med 2002;12(2):106-7 (in chinese).
7. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50(9):329-38.
8. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004;21(6):515-23.
9. Chen Q, Tang YL, Mao PX, Cai ZJ. [Effect of clozapine and risperidone on the glucose-regulating mechanism in schizophrenic patients]. Chin J Clin Rehab 2005;9(4):116-8 (in chinese).
10. World Health Organization. The Asia-Pacific perspective. Redefining obesity and its treatment. International Diabetes Institute. Health Communications Australia Pty Ltd; 2000.
11. Expert Committee on Abnormal Blood Lipids. [Recommendations for the prevention and treatment of abnormal blood lipid]. Chin J Cardiovasc 1997;25:169-75.
12. Si T, He YL, Zhou RY, Wang XD, Shu L, Liu XH. Prescription pattern for patients with schizophrenia in three regions of China. Chin Ment Health J 2003;10:537-40 (in chinese).
13. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54(1):55-9.
14. Sim K, Su A, Chan YH, Shinfuku N, Kua EH, Tan CH. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry Clin Neurosci 2004;58(3):324-9.
15. Bitter I, Chou JC, Ungvari GS, Tang WK, Xiang Z, Iwanami A, et al. Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry 2003;36(4):143-9.
16. Wilson WH, Ban TA, Guy W. Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices. Neuropsychobiology 1985;14(2):75-82.
17. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999;53(Suppl):S35-40.
18. Ruiz S, Chu P, Sramek J, Rotavu E, Herrera J. Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med 1996;63(5-6):306-9.
19. Jin Z. Effect of an open-door policy combined with a structured activity programme on the residual symptoms of schizophrenic in-patients. A six-month randomised controlled trial in Yanbian, Jilin. Br J Psychiatry 1994;24(Suppl):52-7.
20. Peralta V, Cuesta MJ, Caro F, Martinez-Larrea A. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices. Acta Psychiatr Scand 1994;90(5):354-7.
21. Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Can J Psychiatry 1997;42(1):53-7.
22. Galletly CA. Antipsychotic drug doses in a schizophrenia inpatient unit. Aust NZ J Psychiatry 1992;26(4):574-6.
23. Zito JM, Craig TJ, Wanderling J, Siegel C. Pharmacoepidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry 1987;144(6):778-82.
24. Su A, Leong JY, Yip K, Chong MY, Fujii S, Yang S, et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 2004;37(4):175-9.
25. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003;29(3):531-40.
26. Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: A 2-year comparison. J Clin Psychiatry 2003;64(6):673-9.
27. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: A pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 2000;15(3):220-6.
28. Citrome L, Volavka J. The promise of atypical antipsychotics-fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 2004;116(4):49-63.
29. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003;2:CD000440.
30. Martin BC, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: Current trends and five year time series forecasts. Schizophr Res 2001;47:281-92.
31. Mamdani MM, Tu K, Austin PC, Alter DA. Influence of socioeconomic status on drug selection for the elderly in Canada. Ann Pharmacother 2002;36(5):804-8.
32. Apiquian R, Fresan A, de la Fuente-Sandoval C, Ulloa RE, Nicolini H. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry 2004;4(1):12.
33. Chi ZM, Dai AQ, Sun L. [Analysis of Antipsychotic Use for Outpatients]. J Clin Psychol Med 2002;12(2):109-10 (in chinese).
34. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96.
35. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;17(Suppl):41-5.
36. Tang YL, Jiang ZN, Zhai YM, Wu YM. [Screening and evaluation of predictive factors among refractory schizophrenics treated with clozapine]. Chin J Psychiatry 1997;30(3):157-61 (in chinese).
37. Kane JM, Leucht S, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(Suppl 12):1-100.
38. He B, Ding YQ, Wang CY. [Clozapine-induced leukopenia and agranulocytosis in China]. Evaluation Anal Drug Use Hospital China 2003;3(5):307-11 (in chinese).
39. Hou XX, Ying ML, Zhou JD. Changes of white blood cell count among 1434 patients on clozapine. Chin J New Drugs Clin Remedies 1989;8(4):222-4 (in chinese).
40. Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's synopsis of psychiatry: Behavorial sciences, clinical psychiatry, 7th ed. Baltimore, MD: Williams & Wilkins; 1994. p xvi, 1257.
41. Yang JS, Zhang WL. [Clozapine and agranulocytosis]. Shanghai Arch Psychiatry 1990;n2(4):190-1 (in chinese).
42. Chen B, Lu MK. Analysis of 30 cases of clozapine and agranulocytosis. Shanghai Arch Pyschiatry 1997;n9(4):278-9 (in chinese).
43. Lu MK, Hou XX, Ying ML. Analysis of side effects of clozapine. Chin J Neuropyschiatry 1991;24(2):71-4 (in chinese).
44. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New Engl J Med 1993;329(3):162-7.
45. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(Suppl 3):3-7.
46. Wang LW, Wang ZC. Can clozapine be used as a first-line antipsychotic drug? Shanghai Arch Pyschiatry 1999;n11(2):107-11 (in Chinese).
47. Zhao HQ. Handbook of psychotropic treatment, 1st ed. Beijing, China: People's Military Medical Press; 1998. p 836 (in chinese).
48. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002;71(5):244-54.
49. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155(4):499-504.
50. Henderson DC. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001;62(Suppl 23):39-44.
51. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001;111(9):716-23.
52. Liberty IF, Todder D, Umansky R, Harman-Boehm I. Atypical antipsychotics and diabetes mellitus: An association. Isr Med Assoc J 2004;6(5):276-9.
53. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11(1):25-32.